# Chris O’Donnell

> Chris O’Donnell is a Series A investor at Pfizer backing Biotechnology and Mobile. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Pfizer](https://shizune.co/investors/profile/pfizer)
- Total investments: 4
- Last investment: Dec 2025
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/christopherjodonnell/

Chris O’Donnell is a Series A investor at Pfizer focused on Biotechnology and Mobile. Chris O’Donnell is the Partner, Pfizer Ventures & Executive Director, Emerging Sciences & Innovation at Pfizer. Chris O'Donnell attended UC Irvine.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 50% |
| Mobile | 1 | 25% |
| Hardware | 1 | 25% |
| Software | 1 | 25% |
| Biopharma | 1 | 25% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 50% |
| Series B | 2 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Triana Biomedicines | Triana Biomedicines is building the leading molecular glue discovery platform to regulate disease targets that are difficult to address with any other modality. Triana’s drug discovery engine is powered by high- resolution structural insights, state-of-the-art in silico tools, and bespoke chemical libraries. The research team has validated thebest-in-class platform and initiated multiple programs across different disease areas. | $120M | Series B | Dec 03, 2025 |  |
| Somewear Labs | Somewear is a satellite communications solution designed for the increasingly digital world. Somewear is building a satellite-powered platform to keep people safe. Somewear gives any remote operative a reliable line to safety and keeps organizations compliant at a fraction of the traditional cost with a combination of compact satellite hotspots andsoftware designed for low-bandwidth applications.It was founded in 2017 and is based in San Francisco, California. | $13.7M | Series A | Sep 22, 2022 |  |
| Triana Biomedicines | Triana Biomedicines is building the leading molecular glue discovery platform to regulate disease targets that are difficult to address with any other modality. Triana’s drug discovery engine is powered by high- resolution structural insights, state-of-the-art in silico tools, and bespoke chemical libraries. The research team has validated thebest-in-class platform and initiated multiple programs across different disease areas. | $110M | Series A | Apr 06, 2022 |  |
| Pyxis Oncology | Pyxis Oncology is a developer of antibody therapeutics intended to promote the body's immune response to cancer. The company has engaged in deep analyses of tumor antigen-specific tumor-infiltrating lymphocytes (TILs) within hot tumors and of tumor cell signaling pathways within cold tumors, providing laboratories with development of novelantibody-based immunotherapies.It was founded in 2019 and is based in Boston, Massachusetts. | $152M | Series B | Mar 30, 2021 |  |

4 of 4 investments shown.

## Co-investors
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 3 deals together
- [Surveyor Capital](https://shizune.co/investors/profile/surveyor-capital) — VC Fund, 3 deals together
- [Atlas Venture](https://shizune.co/investors/profile/atlas-venture) — VC Fund, 2 deals together
- [Lightspeed Venture Partners](https://shizune.co/investors/profile/lightspeed-venture-partners) — VC Fund, 2 deals together
- [Logos Capital](https://shizune.co/investors/profile/logos-capital) — VC Fund, 2 deals together
- [Acuta Capital Partners](https://shizune.co/investors/profile/acuta-capital-partners) — VC Fund, 1 deal together

## About Pfizer

VC Fund · New York, United States

Pfizer provides access to safe and effective and affordable medicines and health care services. They have a portfolio of products and medicines that support wellness and prevention, as well as treatment and cures for diseases across a broad range of therapeutic areas; and they have an industry-leading pipeline of promising new products that havethe potential to challenge some of the most feared diseases of their time, like Alzheimer's disease and cancer.

5 contacts available at Pfizer.

| Name | Title | Profile |
| --- | --- | --- |
| Alessandra Leone | Global CMC Sr. Manager | https://shizune.co/investors/profile/alessandra-leone |
| Angela L Coral | Senior Manager, Partnerships & Impact Reporting, Global Health & Social Impact | https://shizune.co/investors/profile/angela-l-coral |
| Barbara Dalton | Senior Managing Partner, Pfizer Ventures; VP, Worldwide Business Development | https://shizune.co/investors/profile/barbara-dalton |
| Chris Boshoff | CSO | https://shizune.co/investors/profile/chris-boshoff |
| Chris O’Donnell | Partner, Pfizer Ventures & Executive Director, Emerging Sciences & Innovation | https://shizune.co/investors/profile/chris-o-donnell |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Chris O’Donnell invest in?

Chris O’Donnell invests primarily in Biotechnology, Mobile and Hardware startups, most often at Series A and Series B stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Chris O’Donnell last invest?

The most recent investment recorded for Chris O’Donnell closed in Dec 2025. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co